

Global New Molecular Entity (NME) Drug Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G7B7D7BC2BFBEN.html>

Date: September 2026

Pages: 159

Price: US\$ 3,660.00 (Single User License)

ID: G7B7D7BC2BFBEN

Abstracts

The global New Molecular Entity (NME) Drug market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

New Molecular Entity refers to a chemical structure with certain biological activity. Due to its weak activity, low selectivity, poor absorption, or high toxicity, it cannot be directly used as medicine. However, as a new structural type and clue substance, through structural transformation and modification, drugs with excellent pharmacological effects can be obtained.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “New Molecular Entity (NME) Drug Industry Forecast” looks at past sales and reviews total world New Molecular Entity (NME) Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected New Molecular Entity (NME) Drug sales for 2026 through 2032. With New Molecular Entity (NME) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world New Molecular Entity (NME) Drug industry.

This Insight Report provides a comprehensive analysis of the global New Molecular Entity (NME) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on New Molecular Entity (NME) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global New Molecular Entity (NME) Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for New Molecular Entity (NME) Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global New Molecular Entity (NME) Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of New Molecular Entity (NME) Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:

Antibody

Polypeptide

Small Molecule Drug

Other

Segmentation by Application:

Hospital

Clinic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

UCB

Otsuka Pharmaceutical

Eli Lilly

Genentech

Eisai

Biogen

Menarini Group

GSK

Chest

Travere

Reata

Pfizer

Acadia Pharmaceuticals

Incyte

Cidara

Melinta

Pharming

LEO Pharma

Novartis

Argenx

Takeda

AbbVie

Bayer Hlthcare

Sanofi

Immunocore

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global New Molecular Entity (NME) Drug Market Size (2021-2032)
 - 2.1.2 New Molecular Entity (NME) Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for New Molecular Entity (NME) Drug by Country/Region (2021, 2025 & 2032)
- 2.2 New Molecular Entity (NME) Drug Segment by Type
 - 2.2.1 Antibody
 - 2.2.2 Polypeptide
 - 2.2.3 Small Molecule Drug
 - 2.2.4 Other
 - 2.2.5 New Molecular Entity (NME) Drug Market Size by Type
 - 2.2.5.1 New Molecular Entity (NME) Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.5.2 Global New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)
- 2.3 New Molecular Entity (NME) Drug Segment by Application
 - 2.3.1 Hospital
 - 2.3.2 Clinic
 - 2.3.3 New Molecular Entity (NME) Drug Market Size by Application
 - 2.3.3.1 New Molecular Entity (NME) Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
 - 2.3.3.2 Global New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

3 NEW MOLECULAR ENTITY (NME) DRUG MARKET SIZE BY PLAYER

- 3.1 New Molecular Entity (NME) Drug Market Size Market Share by Player
 - 3.1.1 Global New Molecular Entity (NME) Drug Revenue by Player (2021-2026)
 - 3.1.2 Global New Molecular Entity (NME) Drug Revenue Market Share by Player (2021-2026)
- 3.2 Global New Molecular Entity (NME) Drug Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 NEW MOLECULAR ENTITY (NME) DRUG BY REGION

- 4.1 New Molecular Entity (NME) Drug Market Size by Region (2021-2026)
- 4.2 Global New Molecular Entity (NME) Drug Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas New Molecular Entity (NME) Drug Market Size Growth (2021-2026)
- 4.4 APAC New Molecular Entity (NME) Drug Market Size Growth (2021-2026)
- 4.5 Europe New Molecular Entity (NME) Drug Market Size Growth (2021-2026)
- 4.6 Middle East & Africa New Molecular Entity (NME) Drug Market Size Growth (2021-2026)

5 AMERICAS

- 5.1 Americas New Molecular Entity (NME) Drug Market Size by Country (2021-2026)
- 5.2 Americas New Molecular Entity (NME) Drug Market Size by Type (2021-2026)
- 5.3 Americas New Molecular Entity (NME) Drug Market Size by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC New Molecular Entity (NME) Drug Market Size by Region (2021-2026)
- 6.2 APAC New Molecular Entity (NME) Drug Market Size by Type (2021-2026)
- 6.3 APAC New Molecular Entity (NME) Drug Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe New Molecular Entity (NME) Drug Market Size by Country (2021-2026)
- 7.2 Europe New Molecular Entity (NME) Drug Market Size by Type (2021-2026)
- 7.3 Europe New Molecular Entity (NME) Drug Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa New Molecular Entity (NME) Drug by Region (2021-2026)
- 8.2 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Type (2021-2026)
- 8.3 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL NEW MOLECULAR ENTITY (NME) DRUG MARKET FORECAST

- 10.1 Global New Molecular Entity (NME) Drug Forecast by Region (2027-2032)
 - 10.1.1 Global New Molecular Entity (NME) Drug Forecast by Region (2027-2032)
 - 10.1.2 Americas New Molecular Entity (NME) Drug Forecast
 - 10.1.3 APAC New Molecular Entity (NME) Drug Forecast
 - 10.1.4 Europe New Molecular Entity (NME) Drug Forecast
 - 10.1.5 Middle East & Africa New Molecular Entity (NME) Drug Forecast
- 10.2 Americas New Molecular Entity (NME) Drug Forecast by Country (2027-2032)
 - 10.2.1 United States Market New Molecular Entity (NME) Drug Forecast
 - 10.2.2 Canada Market New Molecular Entity (NME) Drug Forecast
 - 10.2.3 Mexico Market New Molecular Entity (NME) Drug Forecast
 - 10.2.4 Brazil Market New Molecular Entity (NME) Drug Forecast
- 10.3 APAC New Molecular Entity (NME) Drug Forecast by Region (2027-2032)
 - 10.3.1 China New Molecular Entity (NME) Drug Market Forecast
 - 10.3.2 Japan Market New Molecular Entity (NME) Drug Forecast
 - 10.3.3 Korea Market New Molecular Entity (NME) Drug Forecast
 - 10.3.4 Southeast Asia Market New Molecular Entity (NME) Drug Forecast
 - 10.3.5 India Market New Molecular Entity (NME) Drug Forecast
 - 10.3.6 Australia Market New Molecular Entity (NME) Drug Forecast
- 10.4 Europe New Molecular Entity (NME) Drug Forecast by Country (2027-2032)
 - 10.4.1 Germany Market New Molecular Entity (NME) Drug Forecast
 - 10.4.2 France Market New Molecular Entity (NME) Drug Forecast
 - 10.4.3 UK Market New Molecular Entity (NME) Drug Forecast
 - 10.4.4 Italy Market New Molecular Entity (NME) Drug Forecast
 - 10.4.5 Russia Market New Molecular Entity (NME) Drug Forecast
- 10.5 Middle East & Africa New Molecular Entity (NME) Drug Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market New Molecular Entity (NME) Drug Forecast
 - 10.5.2 South Africa Market New Molecular Entity (NME) Drug Forecast
 - 10.5.3 Israel Market New Molecular Entity (NME) Drug Forecast
 - 10.5.4 Turkey Market New Molecular Entity (NME) Drug Forecast
- 10.6 Global New Molecular Entity (NME) Drug Forecast by Type (2027-2032)
- 10.7 Global New Molecular Entity (NME) Drug Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market New Molecular Entity (NME) Drug Forecast

11 KEY PLAYERS ANALYSIS

11.1 UCB

11.1.1 UCB Company Information

11.1.2 UCB New Molecular Entity (NME) Drug Product Offered

11.1.3 UCB New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 UCB Main Business Overview

11.1.5 UCB Latest Developments

11.2 Otsuka Pharmaceutical

11.2.1 Otsuka Pharmaceutical Company Information

11.2.2 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Product Offered

11.2.3 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Otsuka Pharmaceutical Main Business Overview

11.2.5 Otsuka Pharmaceutical Latest Developments

11.3 Eli Lilly

11.3.1 Eli Lilly Company Information

11.3.2 Eli Lilly New Molecular Entity (NME) Drug Product Offered

11.3.3 Eli Lilly New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Eli Lilly Main Business Overview

11.3.5 Eli Lilly Latest Developments

11.4 Genentech

11.4.1 Genentech Company Information

11.4.2 Genentech New Molecular Entity (NME) Drug Product Offered

11.4.3 Genentech New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Genentech Main Business Overview

11.4.5 Genentech Latest Developments

11.5 Eisai

11.5.1 Eisai Company Information

11.5.2 Eisai New Molecular Entity (NME) Drug Product Offered

11.5.3 Eisai New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Eisai Main Business Overview

11.5.5 Eisai Latest Developments

11.6 Biogen

11.6.1 Biogen Company Information

11.6.2 Biogen New Molecular Entity (NME) Drug Product Offered

11.6.3 Biogen New Molecular Entity (NME) Drug Revenue, Gross Margin and Market

Share (2021-2026)

11.6.4 Biogen Main Business Overview

11.6.5 Biogen Latest Developments

11.7 Menarini Group

11.7.1 Menarini Group Company Information

11.7.2 Menarini Group New Molecular Entity (NME) Drug Product Offered

11.7.3 Menarini Group New Molecular Entity (NME) Drug Revenue, Gross Margin and

Market Share (2021-2026)

11.7.4 Menarini Group Main Business Overview

11.7.5 Menarini Group Latest Developments

11.8 GSK

11.8.1 GSK Company Information

11.8.2 GSK New Molecular Entity (NME) Drug Product Offered

11.8.3 GSK New Molecular Entity (NME) Drug Revenue, Gross Margin and Market

Share (2021-2026)

11.8.4 GSK Main Business Overview

11.8.5 GSK Latest Developments

11.9 Chest

11.9.1 Chest Company Information

11.9.2 Chest New Molecular Entity (NME) Drug Product Offered

11.9.3 Chest New Molecular Entity (NME) Drug Revenue, Gross Margin and Market

Share (2021-2026)

11.9.4 Chest Main Business Overview

11.9.5 Chest Latest Developments

11.10 Travers

11.10.1 Travers Company Information

11.10.2 Travers New Molecular Entity (NME) Drug Product Offered

11.10.3 Travers New Molecular Entity (NME) Drug Revenue, Gross Margin and

Market Share (2021-2026)

11.10.4 Travers Main Business Overview

11.10.5 Travers Latest Developments

11.11 Reata

11.11.1 Reata Company Information

11.11.2 Reata New Molecular Entity (NME) Drug Product Offered

11.11.3 Reata New Molecular Entity (NME) Drug Revenue, Gross Margin and Market

Share (2021-2026)

11.11.4 Reata Main Business Overview

11.11.5 Reata Latest Developments

11.12 Pfizer

- 11.12.1 Pfizer Company Information
- 11.12.2 Pfizer New Molecular Entity (NME) Drug Product Offered
- 11.12.3 Pfizer New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
- 11.12.4 Pfizer Main Business Overview
- 11.12.5 Pfizer Latest Developments
- 11.13 Acadia Pharmaceuticals
 - 11.13.1 Acadia Pharmaceuticals Company Information
 - 11.13.2 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Product Offered
 - 11.13.3 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Acadia Pharmaceuticals Main Business Overview
 - 11.13.5 Acadia Pharmaceuticals Latest Developments
- 11.14 Incyte
 - 11.14.1 Incyte Company Information
 - 11.14.2 Incyte New Molecular Entity (NME) Drug Product Offered
 - 11.14.3 Incyte New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 Incyte Main Business Overview
 - 11.14.5 Incyte Latest Developments
- 11.15 Cidara
 - 11.15.1 Cidara Company Information
 - 11.15.2 Cidara New Molecular Entity (NME) Drug Product Offered
 - 11.15.3 Cidara New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Cidara Main Business Overview
 - 11.15.5 Cidara Latest Developments
- 11.16 Melinta
 - 11.16.1 Melinta Company Information
 - 11.16.2 Melinta New Molecular Entity (NME) Drug Product Offered
 - 11.16.3 Melinta New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.16.4 Melinta Main Business Overview
 - 11.16.5 Melinta Latest Developments
- 11.17 Pharming
 - 11.17.1 Pharming Company Information
 - 11.17.2 Pharming New Molecular Entity (NME) Drug Product Offered
 - 11.17.3 Pharming New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)

- 11.17.4 Pharming Main Business Overview
- 11.17.5 Pharming Latest Developments
- 11.18 LEO Pharma
 - 11.18.1 LEO Pharma Company Information
 - 11.18.2 LEO Pharma New Molecular Entity (NME) Drug Product Offered
 - 11.18.3 LEO Pharma New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.18.4 LEO Pharma Main Business Overview
 - 11.18.5 LEO Pharma Latest Developments
- 11.19 Novartis
 - 11.19.1 Novartis Company Information
 - 11.19.2 Novartis New Molecular Entity (NME) Drug Product Offered
 - 11.19.3 Novartis New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.19.4 Novartis Main Business Overview
 - 11.19.5 Novartis Latest Developments
- 11.20 Argenx
 - 11.20.1 Argenx Company Information
 - 11.20.2 Argenx New Molecular Entity (NME) Drug Product Offered
 - 11.20.3 Argenx New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.20.4 Argenx Main Business Overview
 - 11.20.5 Argenx Latest Developments
- 11.21 Takeda
 - 11.21.1 Takeda Company Information
 - 11.21.2 Takeda New Molecular Entity (NME) Drug Product Offered
 - 11.21.3 Takeda New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.21.4 Takeda Main Business Overview
 - 11.21.5 Takeda Latest Developments
- 11.22 AbbVie
 - 11.22.1 AbbVie Company Information
 - 11.22.2 AbbVie New Molecular Entity (NME) Drug Product Offered
 - 11.22.3 AbbVie New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.22.4 AbbVie Main Business Overview
 - 11.22.5 AbbVie Latest Developments
- 11.23 Bayer Hlthcare
 - 11.23.1 Bayer Hlthcare Company Information

- 11.23.2 Bayer Hlthcare New Molecular Entity (NME) Drug Product Offered
- 11.23.3 Bayer Hlthcare New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
- 11.23.4 Bayer Hlthcare Main Business Overview
- 11.23.5 Bayer Hlthcare Latest Developments
- 11.24 Sanofi
 - 11.24.1 Sanofi Company Information
 - 11.24.2 Sanofi New Molecular Entity (NME) Drug Product Offered
 - 11.24.3 Sanofi New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.24.4 Sanofi Main Business Overview
 - 11.24.5 Sanofi Latest Developments
- 11.25 Immunocore
 - 11.25.1 Immunocore Company Information
 - 11.25.2 Immunocore New Molecular Entity (NME) Drug Product Offered
 - 11.25.3 Immunocore New Molecular Entity (NME) Drug Revenue, Gross Margin and Market Share (2021-2026)
 - 11.25.4 Immunocore Main Business Overview
 - 11.25.5 Immunocore Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. New Molecular Entity (NME) Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. New Molecular Entity (NME) Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Antibody

Table 4. Major Players of Polypeptide

Table 5. Major Players of Small Molecule Drug

Table 6. Major Players of Other

Table 7. New Molecular Entity (NME) Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 8. Global New Molecular Entity (NME) Drug Market Size by Type (2021-2026) & (\$ millions)

Table 9. Global New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)

Table 10. New Molecular Entity (NME) Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 11. Global New Molecular Entity (NME) Drug Market Size by Application (2021-2026) & (\$ millions)

Table 12. Global New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

Table 13. Global New Molecular Entity (NME) Drug Revenue by Player (2021-2026) & (\$ millions)

Table 14. Global New Molecular Entity (NME) Drug Revenue Market Share by Player (2021-2026)

Table 15. New Molecular Entity (NME) Drug Key Players Head office and Products Offered

Table 16. New Molecular Entity (NME) Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 17. New Products and Potential Entrants

Table 18. Mergers & Acquisitions, Expansion

Table 19. Global New Molecular Entity (NME) Drug Market Size by Region (2021-2026) & (\$ millions)

Table 20. Global New Molecular Entity (NME) Drug Market Size Market Share by Region (2021-2026)

Table 21. Global New Molecular Entity (NME) Drug Revenue by Country/Region

(2021-2026) & (\$ millions)

Table 22. Global New Molecular Entity (NME) Drug Revenue Market Share by Country/Region (2021-2026)

Table 23. Americas New Molecular Entity (NME) Drug Market Size by Country (2021-2026) & (\$ millions)

Table 24. Americas New Molecular Entity (NME) Drug Market Size Market Share by Country (2021-2026)

Table 25. Americas New Molecular Entity (NME) Drug Market Size by Type (2021-2026) & (\$ millions)

Table 26. Americas New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)

Table 27. Americas New Molecular Entity (NME) Drug Market Size by Application (2021-2026) & (\$ millions)

Table 28. Americas New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

Table 29. APAC New Molecular Entity (NME) Drug Market Size by Region (2021-2026) & (\$ millions)

Table 30. APAC New Molecular Entity (NME) Drug Market Size Market Share by Region (2021-2026)

Table 31. APAC New Molecular Entity (NME) Drug Market Size by Type (2021-2026) & (\$ millions)

Table 32. APAC New Molecular Entity (NME) Drug Market Size by Application (2021-2026) & (\$ millions)

Table 33. Europe New Molecular Entity (NME) Drug Market Size by Country (2021-2026) & (\$ millions)

Table 34. Europe New Molecular Entity (NME) Drug Market Size Market Share by Country (2021-2026)

Table 35. Europe New Molecular Entity (NME) Drug Market Size by Type (2021-2026) & (\$ millions)

Table 36. Europe New Molecular Entity (NME) Drug Market Size by Application (2021-2026) & (\$ millions)

Table 37. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Region (2021-2026) & (\$ millions)

Table 38. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Type (2021-2026) & (\$ millions)

Table 39. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Application (2021-2026) & (\$ millions)

Table 40. Key Market Drivers & Growth Opportunities of New Molecular Entity (NME) Drug

Table 41. Key Market Challenges & Risks of New Molecular Entity (NME) Drug
Table 42. Key Industry Trends of New Molecular Entity (NME) Drug
Table 43. Global New Molecular Entity (NME) Drug Market Size Forecast by Region (2027-2032) & (\$ millions)
Table 44. Global New Molecular Entity (NME) Drug Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global New Molecular Entity (NME) Drug Market Size Forecast by Type (2027-2032) & (\$ millions)
Table 46. Global New Molecular Entity (NME) Drug Market Size Forecast by Application (2027-2032) & (\$ millions)
Table 47. UCB Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 48. UCB New Molecular Entity (NME) Drug Product Offered
Table 49. UCB New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 50. UCB Main Business
Table 51. UCB Latest Developments
Table 52. Otsuka Pharmaceutical Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 53. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Product Offered
Table 54. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 55. Otsuka Pharmaceutical Main Business
Table 56. Otsuka Pharmaceutical Latest Developments
Table 57. Eli Lilly Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 58. Eli Lilly New Molecular Entity (NME) Drug Product Offered
Table 59. Eli Lilly New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 60. Eli Lilly Main Business
Table 61. Eli Lilly Latest Developments
Table 62. Genentech Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 63. Genentech New Molecular Entity (NME) Drug Product Offered
Table 64. Genentech New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 65. Genentech Main Business
Table 66. Genentech Latest Developments
Table 67. Eisai Details, Company Type, New Molecular Entity (NME) Drug Area Served

and Its Competitors

Table 68. Eisai New Molecular Entity (NME) Drug Product Offered

Table 69. Eisai New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 70. Eisai Main Business

Table 71. Eisai Latest Developments

Table 72. Biogen Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 73. Biogen New Molecular Entity (NME) Drug Product Offered

Table 74. Biogen New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 75. Biogen Main Business

Table 76. Biogen Latest Developments

Table 77. Menarini Group Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 78. Menarini Group New Molecular Entity (NME) Drug Product Offered

Table 79. Menarini Group New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 80. Menarini Group Main Business

Table 81. Menarini Group Latest Developments

Table 82. GSK Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 83. GSK New Molecular Entity (NME) Drug Product Offered

Table 84. GSK New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 85. GSK Main Business

Table 86. GSK Latest Developments

Table 87. Chest Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 88. Chest New Molecular Entity (NME) Drug Product Offered

Table 89. Chest New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 90. Chest Main Business

Table 91. Chest Latest Developments

Table 92. Traverso Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 93. Traverso New Molecular Entity (NME) Drug Product Offered

Table 94. Traverso New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 95. Traverso Main Business

Table 96. Traverso Latest Developments

Table 97. Reata Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 98. Reata New Molecular Entity (NME) Drug Product Offered

Table 99. Reata New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 100. Reata Main Business

Table 101. Reata Latest Developments

Table 102. Pfizer Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 103. Pfizer New Molecular Entity (NME) Drug Product Offered

Table 104. Pfizer New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 105. Pfizer Main Business

Table 106. Pfizer Latest Developments

Table 107. Acadia Pharmaceuticals Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 108. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Product Offered

Table 109. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 110. Acadia Pharmaceuticals Main Business

Table 111. Acadia Pharmaceuticals Latest Developments

Table 112. Incyte Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 113. Incyte New Molecular Entity (NME) Drug Product Offered

Table 114. Incyte New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 115. Incyte Main Business

Table 116. Incyte Latest Developments

Table 117. Cidara Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 118. Cidara New Molecular Entity (NME) Drug Product Offered

Table 119. Cidara New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 120. Cidara Main Business

Table 121. Cidara Latest Developments

Table 122. Melinta Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 123. Melinta New Molecular Entity (NME) Drug Product Offered
Table 124. Melinta New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 125. Melinta Main Business
Table 126. Melinta Latest Developments
Table 127. Pharming Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 128. Pharming New Molecular Entity (NME) Drug Product Offered
Table 129. Pharming New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 130. Pharming Main Business
Table 131. Pharming Latest Developments
Table 132. LEO Pharma Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 133. LEO Pharma New Molecular Entity (NME) Drug Product Offered
Table 134. LEO Pharma New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 135. LEO Pharma Main Business
Table 136. LEO Pharma Latest Developments
Table 137. Novartis Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 138. Novartis New Molecular Entity (NME) Drug Product Offered
Table 139. Novartis New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 140. Novartis Main Business
Table 141. Novartis Latest Developments
Table 142. Argenx Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 143. Argenx New Molecular Entity (NME) Drug Product Offered
Table 144. Argenx New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 145. Argenx Main Business
Table 146. Argenx Latest Developments
Table 147. Takeda Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors
Table 148. Takeda New Molecular Entity (NME) Drug Product Offered
Table 149. Takeda New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 150. Takeda Main Business

Table 151. Takeda Latest Developments

Table 152. AbbVie Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 153. AbbVie New Molecular Entity (NME) Drug Product Offered

Table 154. AbbVie New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 155. AbbVie Main Business

Table 156. AbbVie Latest Developments

Table 157. Bayer Hlthcare Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 158. Bayer Hlthcare New Molecular Entity (NME) Drug Product Offered

Table 159. Bayer Hlthcare New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 160. Bayer Hlthcare Main Business

Table 161. Bayer Hlthcare Latest Developments

Table 162. Sanofi Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 163. Sanofi New Molecular Entity (NME) Drug Product Offered

Table 164. Sanofi New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 165. Sanofi Main Business

Table 166. Sanofi Latest Developments

Table 167. Immunocore Details, Company Type, New Molecular Entity (NME) Drug Area Served and Its Competitors

Table 168. Immunocore New Molecular Entity (NME) Drug Product Offered

Table 169. Immunocore New Molecular Entity (NME) Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 170. Immunocore Main Business

Table 171. Immunocore Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. New Molecular Entity (NME) Drug Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global New Molecular Entity (NME) Drug Market Size Growth Rate
(2021-2032) (\$ millions)

Figure 6. New Molecular Entity (NME) Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. New Molecular Entity (NME) Drug Sales Market Share by Country/Region
(2025)

Figure 8. New Molecular Entity (NME) Drug Sales Market Share by Country/Region
(2021, 2025 & 2032)

Figure 9. Global New Molecular Entity (NME) Drug Market Size Market Share by Type
in 2025

Figure 10. New Molecular Entity (NME) Drug in Hospital

Figure 11. Global New Molecular Entity (NME) Drug Market: Hospital (2021-2026) & (\$
millions)

Figure 12. New Molecular Entity (NME) Drug in Clinic

Figure 13. Global New Molecular Entity (NME) Drug Market: Clinic (2021-2026) & (\$
millions)

Figure 14. Global New Molecular Entity (NME) Drug Market Size Market Share by
Application in 2025

Figure 15. Global New Molecular Entity (NME) Drug Revenue Market Share by Player
in 2025

Figure 16. Global New Molecular Entity (NME) Drug Market Size Market Share by
Region (2021-2026)

Figure 17. Americas New Molecular Entity (NME) Drug Market Size 2021-2026 (\$
millions)

Figure 18. APAC New Molecular Entity (NME) Drug Market Size 2021-2026 (\$ millions)

Figure 19. Europe New Molecular Entity (NME) Drug Market Size 2021-2026 (\$
millions)

Figure 20. Middle East & Africa New Molecular Entity (NME) Drug Market Size
2021-2026 (\$ millions)

Figure 21. Americas New Molecular Entity (NME) Drug Value Market Share by Country
in 2025

Figure 22. United States New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 23. Canada New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 24. Mexico New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 25. Brazil New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 26. APAC New Molecular Entity (NME) Drug Market Size Market Share by Region in 2025

Figure 27. APAC New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)

Figure 28. APAC New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

Figure 29. China New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 30. Japan New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 31. South Korea New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 32. Southeast Asia New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 33. India New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 34. Australia New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 35. Europe New Molecular Entity (NME) Drug Market Size Market Share by Country in 2025

Figure 36. Europe New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)

Figure 37. Europe New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

Figure 38. Germany New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 39. France New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 40. UK New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 41. Italy New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$

millions)

Figure 42. Russia New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 43. Middle East & Africa New Molecular Entity (NME) Drug Market Size Market Share by Region (2021-2026)

Figure 44. Middle East & Africa New Molecular Entity (NME) Drug Market Size Market Share by Type (2021-2026)

Figure 45. Middle East & Africa New Molecular Entity (NME) Drug Market Size Market Share by Application (2021-2026)

Figure 46. Egypt New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 47. South Africa New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 48. Israel New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 49. Turkey New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 50. GCC Countries New Molecular Entity (NME) Drug Market Size Growth 2021-2026 (\$ millions)

Figure 51. Americas New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 52. APAC New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 53. Europe New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 54. Middle East & Africa New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 55. United States New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 56. Canada New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 57. Mexico New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 58. Brazil New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 59. China New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 60. Japan New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 61. Korea New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 62. Southeast Asia New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 63. India New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 64. Australia New Molecular Entity (NME) Drug Market Size 2027-2032 (\$

millions)

Figure 65. Germany New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 66. France New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 67. UK New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 68. Italy New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 69. Russia New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 70. Egypt New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 71. South Africa New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 72. Israel New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 73. Turkey New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

Figure 74. Global New Molecular Entity (NME) Drug Market Size Market Share Forecast by Type (2027-2032)

Figure 75. Global New Molecular Entity (NME) Drug Market Size Market Share Forecast by Application (2027-2032)

Figure 76. GCC Countries New Molecular Entity (NME) Drug Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global New Molecular Entity (NME) Drug Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G7B7D7BC2BFBEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7B7D7BC2BFBEN.html>